Distinct Transcriptional Landscapes Identified by ... (ID 1010464) - BioProject

Display Settings:

Format

Summary
BioProject ID list
Accessions List

Send to:

Choose Destination

File
Clipboard
Collections
My Bibliography

Links from SRA

Accession: PRJNA1010464 ID: 1010464

Distinct Transcriptional Landscapes Identified by Radiographic Response in Metastatic Triple-Negative Breast Cancer Treated with Carboplatin, Nab-Paclitaxel, and Pembrolizumab in a Single-Arm Phase II Trial (human)

See Genome Information for Homo sapiens

Navigate Across

97830 additional projects are related by organism.

A single arm, Phase II trial of carboplatin, nab-paclitaxel, and pembrolizumab (CNP) in metastatic triple negative breast cancer (mTNBC) was designed to evaluate overall response rate (ORR), progression-free survival (PFS), duration of response (DOR), safety/tolerability, and identify pathologic and transcriptomic correlates of response to therapy. More...

Accession	PRJNA1010464; GEO: GSE241876
Data Type	Transcriptome or Gene expression
Scope	Multiisolate
Organism	Homo sapiens[Taxonomy ID: 9606] Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo; Homo sapiens
Publications	Wilkerson AD et al., "Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer.", Clin Cancer Res, 2024 Jan 5;30(1):82-93
Submission	Registration date: 29-Aug-2023 CLEVELAND CLINIC LERNER COM-CWRU
Relevance	Medical

Project Data:

Resource Name	Number of Links
Sequence data
SRA Experiments	19
Publications
PubMed	1
PMC	1
Other datasets
BioSample	19
GEO DataSets	1

GEO Data Details

Parameter	Value
Data volume, Supplementary Mbytes	6

SRA Data Details

Parameter	Value
Data volume, Gbases	342
Data volume, Tbytes	0.11

BioProject

Result Filters

Display Settings:

Send to:

Links from SRA

Distinct Transcriptional Landscapes Identified by Radiographic Response in Metastatic Triple-Negative Breast Cancer Treated with Carboplatin, Nab-Paclitaxel, and Pembrolizumab in a Single-Arm Phase II Trial (human)

Supplemental Content

Related information

Recent activity